Mycenax Biotech Inc. held the opening ceremony for its "Automated Multi-Function" fill-finish line on October 16th 2024. This fill-finish line, with an investment of NT$700 million, incorporates globally renowned German brand Optima’s automated fill-finish line and sterile isolation devices (including filling machines, freeze dryers, and isolators). It features a flexible design capable of filling various types and sizes, allowing for quick changeovers that enhance production flexibility and improve product quality, thus providing high-quality, sterile filling solutions for various biopharmaceuticals.
The fill-finish line can accommodate multiple types, including liquid vials, lyophilized vials, and pre-filled syringes. Specifically, for liquid vials, it can fill various sizes ranging from 2R to 10R, depending on requirements. Additionally, this fill-finish line boasts a high degree of automation, achieving a maximum output of 10,000 vials/syringes per hour and over 8 million vials/syringes annually. It is the first high-flexibility automated fill-finish line in Taiwan capable of meeting the diverse needs for both small-batch clinical trial products and large-scale commercial drug production.
Mycenax Biotech Inc.'s GMP plant 2 has a production line with a capacity of 12,000L for active pharmaceutical ingredients (API). The addition of this automated fill-finish line, which can produce 8 million vials/syringes annually, positions Mycenax as the only CDMO in Taiwan able to provide comprehensive, high-quality biopharmaceutical services. The GMP plant 2 will assist clients in enhancing production efficiency and effectively reducing costs, marking a significant advantage and highlight for Mycenax.
About Mycenax
Mycenax takes the CDMO brand positioning of "big D and medium M" with "Innovative development abilities (D) and Adequate manufacturing capacity (M)" to provides one-stop services for the development and manufacture of traditional biologics and novel biological drugs. At its core, Mycenax is committed to the development and production of biological drugs, from the R&D phase to cGMP manufacturing plants to drug commercialization. Mycenax, as an international CDMO company, continuously invests in product development innovations and technology platform optimizations in order to provide customers with comprehensive and streamlined CDMO services. Mycenax Biotech currently has a capital of 2.06 billion NTD.
Stock code: Mycenax Biotech (4726).
Company website: http://www.mycenax.com
Press Contact:
Liru Yeh
Email: liru.yeh@mycenax.com
Mycenax Biotech Inc. held the opening ceremony for its "Automated Multi-Function" fill-finish line on October 16th 2024. This fill-finish line, with an investment of NT$700 million, incorporates globally renowned German brand Optima’s automated fill-finish line and sterile isolation devices (including filling machines, freeze dryers, and isolators). It features a flexible design capable of filling various types and sizes, allowing for quick changeovers that enhance production flexibility and improve product quality, thus providing high-quality, sterile filling solutions for various biopharmaceuticals.
The fill-finish line can accommodate multiple types, including liquid vials, lyophilized vials, and pre-filled syringes. Specifically, for liquid vials, it can fill various sizes ranging from 2R to 10R, depending on requirements. Additionally, this fill-finish line boasts a high degree of automation, achieving a maximum output of 10,000 vials/syringes per hour and over 8 million vials/syringes annually. It is the first high-flexibility automated fill-finish line in Taiwan capable of meeting the diverse needs for both small-batch clinical trial products and large-scale commercial drug production.
Mycenax Biotech Inc.'s GMP plant 2 has a production line with a capacity of 12,000L for active pharmaceutical ingredients (API). The addition of this automated fill-finish line, which can produce 8 million vials/syringes annually, positions Mycenax as the only CDMO in Taiwan able to provide comprehensive, high-quality biopharmaceutical services. The GMP plant 2 will assist clients in enhancing production efficiency and effectively reducing costs, marking a significant advantage and highlight for Mycenax.
About Mycenax
Mycenax takes the CDMO brand positioning of "big D and medium M" with "Innovative development abilities (D) and Adequate manufacturing capacity (M)" to provides one-stop services for the development and manufacture of traditional biologics and novel biological drugs. At its core, Mycenax is committed to the development and production of biological drugs, from the R&D phase to cGMP manufacturing plants to drug commercialization. Mycenax, as an international CDMO company, continuously invests in product development innovations and technology platform optimizations in order to provide customers with comprehensive and streamlined CDMO services. Mycenax Biotech currently has a capital of 2.06 billion NTD.
Stock code: Mycenax Biotech (4726).
Company website: http://www.mycenax.com
Press Contact:
Liru Yeh
Email: liru.yeh@mycenax.com